Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06998134 · ClinicalTrials.gov registry record
Toward Ubiquitous Lower Limb Exoskeleton Use in Children and Young Adults
A clinical trial of Muscle Weakness and Problems Moving Their Arms and Legs, sponsored by National Institutes of Health Clinical Center (CC).
- Recruiting
- Registry status
- 23
- Enrollment target
- 1
- Study location
NCT06998134: Recruiting study of Muscle Weakness and Problems Moving Their Arms and Legs, sponsored by National Institutes of Health Clinical Center (CC).
NCT06998134 is a study of Muscle Weakness and Problems Moving Their Arms and Legs that is actively recruiting participants, run by National Institutes of Health Clinical Center (CC). The registered enrollment target is 23 participants, below the 74-participant average among 25 other Muscle Weakness trials with a reported enrollment target (69% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06998134, a study of Muscle Weakness and Problems Moving Their Arms and Legs, is actively recruiting participants, sponsored by National Institutes of Health Clinical Center (CC).
- RECRUITING
- Registry status
- 23 participants
- Enrollment target
- 1
- Study location
Study Summary
People with cerebral palsy (CP), muscular dystrophy (MD), spina bifida, or spinal cord injury often have muscle weakness, and problems moving their arms and legs. The NIH designed a new brace device, called an exoskeleton, that is worn on the legs and helps people walk. This study is investigating new ways the exoskeleton can be used in multiple settings while performing different walking or movement tasks, which we call ubiquitous use. For example, we will ask you to walk on a treadmill at different speeds, walk up and down a ramp, or walk through an obstacle course. Optionally, the exoskeletons may also use functional electrical stimulation (FES), a system that sends electrical pulses to the muscle to help it move the limb.
Primary Outcome
To evaluate knee extension deficiency, we will use:1) Peak knee extension and2) Range of knee angle excursion (difference between maximum extension and flexion).These endpoints will be measured and compared between each control strategy within each task during the assessment visit.
Conditions Studied
Interventions
- DEVICE Extension assist knee ankle foot orthosis (EA-KAFO)
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2026-03-26 |
| Est. Completion | 2028-08-18 |
What NCT06998134 shows while recruiting
NCT06998134 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 74-participant average among 25 other Muscle Weakness trials with a reported enrollment target (69% lower).
The record links to 2 conditions, with Muscle Weakness appearing as the primary indexed condition, and to 1 intervention - of which Extension assist knee ankle foot orthosis (EA-KAFO) is the first listed.
NCT06998134 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT06998134 about?
NCT06998134 is a clinical study titled "Toward Ubiquitous Lower Limb Exoskeleton Use in Children and Young Adults". People with cerebral palsy (CP), muscular dystrophy (MD), spina bifida, or spinal cord injury often have muscle weakness, and problems moving their arms and legs. The NIH designed a new brace device, called an exoskeleton, that is worn on the legs and helps people walk. This study is investigating n...
What is the current status of trial NCT06998134?
This trial is currently recruiting. The enrollment target is 23 participants. The study started on 2026-03-26. Estimated completion is 2028-08-18.
What conditions does trial NCT06998134 study?
This clinical trial studies the following conditions: Muscle Weakness, Problems Moving Their Arms and Legs.
What interventions are being tested in trial NCT06998134?
The interventions under investigation include: Extension assist knee ankle foot orthosis (EA-KAFO) (DEVICE).
Who is sponsoring clinical trial NCT06998134?
This trial is sponsored by National Institutes of Health Clinical Center (CC), which has 338 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06998134 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Muscle Weakness
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06998134's enrollment target sits among peer trials
23 21st of 25 higher than 5 of 25 other Muscle Weakness trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Muscle Weakness trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effect of Weight Loss on Intermuscular Adipose Tissue (IMAT) Signaling
RECRUITING · NA
-
FIT Exercise in 30d of ULLS-induced Muscle Disuse
RECRUITING · NA
-
Muscle Recovery After Critical Illness
RECRUITING
-
THRIVE Well Cancer FDTN/Exercise_Creatine Supplementation
RECRUITING · NA
-
A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases
RECRUITING · Phase 1
-
Depo-Medrol on Psoas After LLIF
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI